Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it. Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
DAVID HERZBERG is Professor of History and Director of the interdisciplinary Drugs, Health, and Society MA Program at the University at Buffalo-SUNY.
JOSEPH M. GABRIEL is Associate Professor of medical history at Florida State University.
NILS KESSEL is Maître de conférences (Assoc. Prof.) of history of medicine, science and technology at Université de Strasbourg.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. 2026. hardcover. . . . . . N° de réf. du vendeur V9781648251696
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Hardcover. Etat : Brand New. 398 pages. In Stock. N° de réf. du vendeur __1648251692
Quantité disponible : 2 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. N° de réf. du vendeur 408583636
Quantité disponible : 3 disponible(s)
Vendeur : Kennys Bookstore, Olney, MD, Etats-Unis
Etat : New. 2026. hardcover. . . . . . Books ship from the US and Ireland. N° de réf. du vendeur V9781648251696
Quantité disponible : Plus de 20 disponibles
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. N° de réf. du vendeur 26405651979
Quantité disponible : 3 disponible(s)
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it.Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9781648251696
Quantité disponible : 1 disponible(s)
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Hardcover. Etat : new. Hardcover. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it.Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9781648251696
Quantité disponible : 1 disponible(s)